
    
      The objective of this study is to evaluate the safety and efficacy of ophthalmic intravitreal
      injection of ALG - 1001 in human subjects with diabetic macular edema. The primary endpoint
      of this study is observation of dose limiting toxicity and maximum tolerated dose. The
      secondary endpoint of this study is observation of a clinical effect in best corrected visual
      acuity (BCVA) (ETDRS letters) and OCT central macular thickness.
    
  